Abstract
Purpose Bone-seeking radiopharmaceuticals have palliative benefit in castration-resistant prostate cancer (CRPC) metastatic to bone. Recent studies have shown improvement of survival and quality of life when radiopharmaceuticals were given repeatedly or in combination with chemotherapy. We designed a phase I study combining docetaxel and Re-186-labelled hydroxyethylidene diphosphonate (HEDP) in men with CRPC and bone metastases to evaluate toxicity.
Original language | English |
---|---|
Pages (from-to) | 1990-1998 |
Number of pages | 9 |
Journal | European Journal of Nuclear Medicine and Molecular Imaging |
Volume | 38 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2011 |
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging